Publicaciones en colaboración con investigadores/as de Oslo University Hospital (19)

2023

  1. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

2022

  1. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 4, pp. 406-419

  2. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 2, pp. 187-210

  3. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 7, pp. 738-751

  4. Toward personalized medicine for cardiovascular pharmacotherapy

    European Heart Journal

2021

  1. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders

    European Neuropsychopharmacology, Vol. 48, pp. 49-88

  2. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 3, pp. 239-250

  3. Repurposed antiviral drugs for COVID-19 — InteriM WHO solidarity trial results

    New England Journal of Medicine, Vol. 384, Núm. 6, pp. 497-511

  4. The age of randomized clinical trials: Three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 5, pp. 453-459

  5. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 6, pp. 557-567

2020

  1. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: Systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 86-93

2019

  1. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 3, pp. 171-180

2018

  1. Antiarrhythmic drugs-clinical use and clinical decision making: A consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP)

    Europace, Vol. 20, Núm. 5, pp. 731-732

  2. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 3, pp. 180-188

  3. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal, Vol. 39, Núm. 24, pp. 2274-2281

  4. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 4, pp. 230-236

2017

  1. Gender differences in the effects of cardiovascular drugs

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 3, Núm. 3, pp. 163-182

2016

  1. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal

  2. Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014

    Psychiatric Genetics, Vol. 26, Núm. 1, pp. 1-47